Stockscreener 앱 받기
2.73
3.53%
-0.10
전일 마감가:
$2.83
열려 있는:
$2.88
하루 거래량:
31,006
Relative Volume:
0.77
시가총액:
$8.20M
수익:
-
순이익/손실:
$-29.77M
주가수익비율:
-2.703
EPS:
-1.01
순현금흐름:
$-24.23M
1주 성능:
+0.74%
1개월 성능:
+7.06%
6개월 성능:
-46.26%
1년 성능:
-66.96%
1일 변동 폭
$2.702
$2.9332
1주일 범위
$2.47
$2.9332
52주 변동 폭
$2.115
$15.75
Moleculin Biotech Inc Stock (MBRX) Company Profile
명칭
Moleculin Biotech Inc
전화
713-300-5160
주소
5300 MEMORIAL DRIVE, HOUSTON, TX
MBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| MBRX | 2.73 | 8.20M | 0 | -29.77M | -24.23M | -1.01 |
| VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Moleculin Biotech Inc Stock (MBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-07-18 | 재개 | Oppenheimer | Outperform |
Moleculin Biotech Inc 주식(MBRX)의 최신 뉴스
Financial Comparison: Moleculin Biotech (NASDAQ:MBRX) & RedHill Biopharma (NASDAQ:RDHL) - Defense World
Moleculin Biotech Corporate Presentation Posted on Company WebsiteOn November 18, 2024, Moleculin Biotech, Inc. made public a corporate presentation on its official website. This presentation, identified as Exhibit 99.1 in the Current Report on Form - Defense World
What is Roth Capital’s Forecast for MBRX Q1 Earnings? - Defense World
Moleculin Biotech Unveils New Corporate Presentation - TipRanks
New Findings Show Moleculin's Annamycin Overcomes Resistance to Venetoclax in AML - PR Newswire
Moleculin Biotech Amends Clinical Trial Protocol for Phase 3 Trial - Defense World
Armistice Capital, LLC Expands Portfolio with Moleculin Biotech Inc Acquisition - GuruFocus.com
Moleculin (MBRX) Stock Jumps On Accelerated Clinical Trial News - Stocks Telegraph
Moleculin Biotech, Inc. Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia Pivotal Trial to H2 2025 - Marketscreener.com
Moleculin Biotech advances Annamycin AML trial protocol - Investing.com
Moleculin Biotech Accelerates Annamycin Phase 3 Trial - TipRanks
Moleculin Accelerates Planned Unblinded Data Readout for MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial to H2 2025 - PR Newswire
Maxim Group Has Lowered Expectations for Moleculin Biotech (NASDAQ:MBRX) Stock Price - Defense World
Moleculin Biotech Reports Financial Highlights and Future Plans - Yahoo Finance
Moleculin gets IRB nod for Phase 3 AML trial - Investing.com India
Moleculin Biotech, Inc. (NASDAQ:MBRX) Q3 2024 Earnings Call Transcript - Insider Monkey
Moleculin gets IRB nod for Phase 3 AML trial By Investing.com - Investing.com Nigeria
Moleculin Receives Institutional Review Board Approval for MIRACLE Phase 3 Pivotal Trial of Annamycin in Combination with Cytarabine for the Treatment of R/R Acute Myeloid Leukemia (AML) - PR Newswire
Earnings call: Moleculin Biotech optimistic on Annamycin's trial By Investing.com - Investing.com Australia
Moleculin Reports Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire
Moleculin Biotech Inc. (MBRX) Quarterly 10-Q Report - Quartz
Moleculin Biotech, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Moleculin Biotech (MBRX) Set to Announce Quarterly Earnings on Friday - Defense World
Moleculin to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast - StreetInsider.com
Moleculin Biotech : to Report Third Quarter 2024 Financial Results on November 8, 2024 and Host Conference Call and Webcast Form 8 K - Marketscreener.com
Moleculin Biotech (NASDAQ:MBRX) Earns Sell Rating from Analysts at StockNews.com - Defense World
Moleculin Appoints Leading Expert in Pancreatic Cancer to its Scientific Advisory Board to Support Development of Annamycin - Star Local Media
Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AML - GuruFocus.com
Soft Tissue Sarcoma Market Growth to Accelerate in Forecast - openPR
Moleculin Biotech (NASDAQ:MBRX) Research Coverage Started at StockNews.com - Defense World
Moleculin Biotech stockholders approve new stock plan By Investing.com - Investing.com South Africa
Moleculin to Participate in the Virtual Investor Lunch Break: Th - GuruFocus.com
Moleculin Abstract Accepted for Poster Presentation at the Europ - GuruFocus.com
Moleculin Biotech stockholders approve new stock plan - Investing.com India
Moleculin Biotech’s Annual Meeting Decisions and Elections - TipRanks
Moleculin Biotech (NASDAQ:MBRX) versus Equillium (NASDAQ:EQ) Financial Comparison - Defense World
Moleculin Biotech Highlights Annamycin’s AML Treatment Potential - Yahoo Finance
Transcript from Moleculin's Recent Virtual Acute Myeloid Leukemia KOL Event Now Available - Financial Times
Ependymoma Market to Rise by 2032, DelveInsight | Fera - openPR
StockNews.com Begins Coverage on Moleculin Biotech (NASDAQ:MBRX) - Defense World
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ... - Yahoo Finance
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: P - GuruFocus.com
Moleculin Announces Proposed Underwritten Public Offering - Marketscreener.com
Moleculin Announces Full Exercise of Over-Allotment Option - Marketscreener.com
Moleculin Biotech Hosts Virtual AML KOL Event and Trial Update - TipRanks
Moleculin to Host Virtual Acute Myeloid Leukemia KOL Event on October 14, 2024 - Marketscreener.com
Moleculin Biotech (NASDAQ:MBRX) Now Covered by StockNews.com - Defense World
Moleculin to Present at Two Upcoming Investor Conferences - Marketscreener.com
Moleculin Biotech (NASDAQ:MBRX) Now Covered by Analysts at StockNews.com - Defense World
Moleculin to Present at Two Upcoming Investor Conferences – Company Announcement - Financial Times
Moleculin Biotech Releases Updated Corporate Presentation - TipRanks
Moleculin Biotech Inc (MBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.89%
2.08%
자본화:
|
볼륨(24시간):